Utilizing An Integrated Cell Line Development Approach With High Producing Stable Pools

The increasing number of protein-based therapeutics entering the drug development pipeline has intensified the need for efficient and expedited development processes. Cell line development (CLD) plays a pivotal role in this regard, as it can significantly reduce timelines to regulatory submission. A well-structured CLD strategy, coupled with advanced technologies, can enhance productivity, minimize risks, and optimize the overall development pathway.

This presentation delves into how Abzena's innovative CLD technologies, such as AbZelect™ and AbZelectPRO™, can accelerate the generation of high-producing stable pools in early-stage development. By leveraging these technologies, drug developers can expedite non-clinical activities and ultimately shorten the time to regulatory submission.

Explore how an integrated CLD approach, combined with cutting-edge technologies, can drive program success and accelerate the development of protein-based therapeutics.